A detailed history of State Street Corp transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 7,153,280 shares of CCCC stock, worth $33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,153,280
Previous 155,373 4503.94%
Holding current value
$33 Million
Previous $877,000 6563.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$5.3 - $11.0 $37.1 Million - $77 Million
6,997,907 Added 4503.94%
7,153,280 $58.4 Million
Q2 2023

Aug 14, 2023

SELL
$2.75 - $3.77 $1.7 Million - $2.33 Million
-618,848 Reduced 79.93%
155,373 $427,000
Q1 2023

May 15, 2023

SELL
$3.1 - $9.02 $5.19 Million - $15.1 Million
-1,673,376 Reduced 68.37%
774,221 $2.43 Million
Q4 2022

Feb 14, 2023

BUY
$5.42 - $10.24 $2.63 Million - $4.97 Million
485,785 Added 24.76%
2,447,597 $14.4 Million
Q3 2022

Nov 15, 2022

BUY
$8.03 - $12.77 $10 Million - $15.9 Million
1,245,369 Added 173.83%
1,961,812 $17.2 Million
Q2 2022

Aug 15, 2022

SELL
$5.06 - $26.46 $7.65 Million - $40 Million
-1,511,316 Reduced 67.84%
716,443 $5.4 Million
Q1 2022

May 16, 2022

BUY
$19.99 - $33.23 $12.8 Million - $21.2 Million
638,006 Added 40.13%
2,227,759 $54 Million
Q4 2021

Feb 14, 2022

SELL
$29.39 - $46.86 $2.02 Million - $3.23 Million
-68,877 Reduced 4.15%
1,589,753 $51.2 Million
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $10.3 Million - $14.5 Million
288,008 Added 21.01%
1,658,630 $74.1 Million
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $15.4 Million - $21.4 Million
507,389 Added 58.78%
1,370,622 $51.9 Million
Q1 2021

May 17, 2021

BUY
$31.96 - $46.5 $22.3 Million - $32.5 Million
698,102 Added 422.76%
863,233 $31.9 Million
Q4 2020

Feb 16, 2021

BUY
$22.8 - $37.05 $3.76 Million - $6.12 Million
165,131 New
165,131 $5.47 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $226M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.